Benchmark reiterated their speculative buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH - Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $17.00 price target on the stock.
Separately, HC Wainwright reaffirmed a buy rating and set a $20.00 price target on shares of Reviva Pharmaceuticals in a research note on Monday, March 25th.
Get Our Latest Stock Report on Reviva Pharmaceuticals
Reviva Pharmaceuticals Stock Performance
Shares of NASDAQ:RVPH traded down $0.15 during midday trading on Tuesday, reaching $3.33. The company's stock had a trading volume of 93,440 shares, compared to its average volume of 326,585. The firm has a 50 day moving average price of $3.73 and a two-hundred day moving average price of $4.18. Reviva Pharmaceuticals has a fifty-two week low of $2.67 and a fifty-two week high of $9.25. The firm has a market capitalization of $92.97 million, a price-to-earnings ratio of -1.99 and a beta of -0.02.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Reviva Pharmaceuticals in the third quarter worth approximately $27,000. Wells Fargo & Company MN raised its stake in shares of Reviva Pharmaceuticals by 4,550.0% in the second quarter. Wells Fargo & Company MN now owns 5,115 shares of the company's stock worth $30,000 after purchasing an additional 5,005 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Reviva Pharmaceuticals in the first quarter worth approximately $31,000. Raymond James & Associates purchased a new stake in shares of Reviva Pharmaceuticals in the first quarter worth approximately $34,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Reviva Pharmaceuticals in the fourth quarter worth approximately $52,000. 63.18% of the stock is owned by institutional investors and hedge funds.
Reviva Pharmaceuticals Company Profile
(
Get Free Report)
Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.
Further Reading
Before you consider Reviva Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reviva Pharmaceuticals wasn't on the list.
While Reviva Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
